Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

HEMOLEVEN® Expanded Access Program for Prevention of Surgical and Postpartum Hemorrhage in Patients With Severe Inherited Factor XI Deficiency

NCT01701947 is registered in ClinicalTrials.gov with Laboratoire français de Fractionnement et de Biotechnologies as lead sponsor.

NCT NCT01701947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01701947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
HEMOLEVEN® Expanded Access Program for Prevention of Surgical and Postpartum Hemorrhage in Patients With Severe Inherited Factor XI Deficiency
Lead sponsor
Laboratoire français de Fractionnement et de Biotechnologies
Phase
Expanded access
Overall status
No longer available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

postpartum hemorrhage, surgery, wound; rupture, surgery, cesarean section